Id: acc3649
Group: 1sens
Protein: pRb
Gene Symbol: RB1
Protein Id: P06400
Protein Name: RB_HUMAN
PTM: phosphorylation
Site: Thr373
Site Sequence: EEVNVIPPHTPVRTVMNTIQQ
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: Myeloid Leukemia
Disease Cellline: MV4-11
Disease Info:
Drug: Transforming growth factor beta
Drug Info: "Transforming growth factor beta is a cytokine that plays a crucial role in various cellular processes such as cell growth, differentiation, and apoptosis."
Effect: no effect
Effect Info: Transforming growth factor beta dephosphorylates pRB in tumor cells.
Note: no effect
Score: 2.0
Pubmed(PMID): 11027571
Sentence Index:
Sentence:

Sequence & Structure:

MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
RB1-Thr373
Cancer Intensity
BRCA 2.526
COAD -0.21
HGSC 0.331
ccRCC -0.437
GBM -0.531
HNSC 0.068
LUAD -1.274
LUSC 0.565
non_ccRCC -0.98
PDAC -0.234
UCEC 0.175

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 780 D Meningioma Phosphorylation 31615938
- - D Colon cancer/carcinoma Phosphorylation 11032757
S 795 D Skin cancer Phosphorylation 23888052
S 807 D Skin cancer Phosphorylation 23888052
S 807 D Ovarian cancer/carcinoma Phosphorylation 28319064
S 811 D Skin cancer Phosphorylation 23888052
S 780 P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 16648554
- - P Lung cancer/carcinoma Phosphorylation 9393586
- - P Head and neck squamous cell carcinoma Phosphorylation 23414419
Y 805 P Chronic myelogenous leukemia Phosphorylation 16158058
Y 805 P Chronic myelogenous leukemia/chronic myeloid leukemia Phosphorylation 16158058
S 811 U Neuroendocrine cancer/carcinoma Phosphorylation 24135281
- - U Retinoblastoma Phosphorylation 11900540
- - U Acute lymphoblastic leukemia Phosphorylation 11380466
S 807 U Bladder cancer Phosphorylation 22787429
S 807 U Neuroendocrine cancer/carcinoma Phosphorylation 24135281
S 811 U Bladder cancer Phosphorylation 22787429
K 720 U Uveal melanoma SUMOylation 34839558
S 780 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 23408967
S 795 U Melanoma Phosphorylation 15502804 ;  15502804 ;  15502804
S 807 U Melanoma Phosphorylation 15502804 ;  10969768 ;  10969768 ;  15502804 ;  15502804
S 807 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 23408967
S 811 U Melanoma Phosphorylation 15502804 ;  15502804
S 811 U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 23408967
S 608 U Cervical cancer Phosphorylation 33516252
S 807 U Cervical cancer Phosphorylation 33516252
K 810 U Bladder cancer Methylation 22787429
Y 805 U Chronic myelogenous leukemia Phosphorylation 16158058
S 249 U Breast cancer/tumor/carcinoma Phosphorylation 17599043
S 780 U Breast cancer Phosphorylation 36797347
S 780 U Hepatocellular carcinoma/hepatocarcinoma/hepatoma Phosphorylation 15349907
S 807 U Intraocular melanoma Phosphorylation 10969768 ;  10969768
S 811 U Intraocular melanoma Phosphorylation 10969768 ;  10969768
T 252 U Breast cancer/tumor/carcinoma Phosphorylation 17599043
T 356 U Ovarian cancer/carcinoma Phosphorylation 28319064
T 356 U Squamous cell carcinoma Phosphorylation 26265441
T 821 U Breast cancer/tumor/carcinoma Phosphorylation 22895174 ;  10353599
- - U Nasopharyngeal carcinoma Phosphorylation 18697201
- - U Hepatocellular carcinoma Phosphorylation 36031658
- - U Ulcerative colitis Phosphorylation 23967107
- - U Crohn's disease Phosphorylation 23967107
- - U Breast cancer/tumor/carcinoma Phosphorylation 23686806
- - U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 24107447
- - U Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 24334458
- - U Neuroblastoma Phosphorylation 10644979
- - U Breast cancer/tumor/carcinoma Phosphorylation 10860819
- - U Neuroblastoma Phosphorylation 16824683

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Pictilisib 6.6465 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Dactolisib 6.1115 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Dactolisib 2 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Dasatinib 8.1919 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Dasatinib 8.1435 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Dasatinib 5.923 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Dasatinib 4.8236 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Nintedanib 8.7745 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Nintedanib 7.7944 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 PD325901 8.5086 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 PD325901 7.7438 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 AZD8055 6.9941 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Pictilisib 4.2208 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Refametinib 6.1189 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Refametinib 6.0019 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Staursporin 15 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Staursporin 6.9619 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 Tideglusib 10.6752 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A549 Tideglusib 6.7768 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR K562 Paclitaxel 8.8159 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR K562 Paclitaxel 7.4762 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 2 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Afatinib 5.497 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Afatinib 8.6822 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Afatinib 8.2067 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Afatinib 10.0141 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Afatinib 7.2825 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 5.866 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 5.4109 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 7.3123 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 6.3292 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 7.4415 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Afatinib 3.9617 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Dasatinib 2 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 5.3113 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 5.5498 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 5.49 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 9.278 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 6.5653 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 9.464 -
P06400 RB1 P Thr373 SNLDEEVNVIPPHT(ph)PVR A431 Gefitinib 8.272 -
P06400 RB1 P Thr373 KSNLDEEVNVIPPHT(ph)PVR A549 AZD8055 8.8059 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: